There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report), Oric Pharmaceuticals (ORIC – Research Report) and Acadia Healthcare (ACHC – Research Report) with bullish sentiments.
Werewolf Therapeutics (HOWL)
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Werewolf Therapeutics on November 3. The company’s shares closed last Tuesday at $2.94.
According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of
Werewolf Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.25, a 337.5% upside from current levels. In a report issued on October 24, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
See the top stocks recommended by analysts >>
Oric Pharmaceuticals (ORIC)
Robert W. Baird analyst Colleen M. Kusy reiterated a Buy rating on Oric Pharmaceuticals on November 6 and set a price target of $27.00. The company’s shares closed last Tuesday at $6.85.
According to TipRanks.com, Kusy is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oric Pharmaceuticals with a $17.17 average price target, a 152.5% upside from current levels. In a report released yesterday, Oppenheimer also upgraded the stock to Buy with a $14.00 price target.
Acadia Healthcare (ACHC)
Leerink Partners analyst Whit Mayo reiterated a Buy rating on Acadia Healthcare on November 6 and set a price target of $95.00. The company’s shares closed last Tuesday at $74.29.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acadia Healthcare with a $90.40 average price target, implying a 23.1% upside from current levels. In a report issued on November 6, TD Cowen also maintained a Buy rating on the stock with a $86.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HOWL:
- Werewolf Therapeutics price target raised to $15 from $12 at Jefferies
- Werewolf present preliminary data from Phase 1/1b trial for WTX-124
- Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf abstract shows positive signals for WTX-124, says H.C. Wainwright
- Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
